Sandoz - PharmaVitae Generics Profile

Publication Date	October 2007
Publisher	Datamonitor
Product Type	Report
Pages	55
ISBN Number	not applicable
Product Code	DAT08911

Price

£2,000.00
approximately: $3,454 | €2,539

PRINT £2,000 ($3,454 | €2,539)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Sandoz in the generic pharmaceutical sector. The profile encompasses global company strategy, generic and biosimilar portfolio and pipeline analysis and assessment of financial performance. An interactive data and analysis tool provides quantitative and qualitative information.

Reasons to Purchase

Benchmark Sandoz's performance against key rivals in the generic pharmaceutical sector
Evaluate Sandoz's historical and forecast generic growth drivers and resistors
Understand the strategy behind Sandoz's recent launch of its first biosimilar, Omnitrope

Content

Chapter 1 Executive Summary
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic focus
- Generic drug outlook, 2006-12
- Generic drug launch history
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 2 Corporate History
- Key findings
- Background
- Key corporate developments
- M&A history
- Hexal acquisition
- Eon Labs acquisition
- M&A strategy
- Deals and alliances
- Current corporate structure
- Current management team
Chapter 3 Historical Performance
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate versus generic peer set
- Product analysis, 2001-06
- Growth drivers
- Generic drugs
- Growth resistors
- Operating revenue and cost analysis, 2002-06
- Operating revenue/cost analysis
Chapter 4 Brand Forecast Performance
Chapter 5 Key Products and Competitors
- Key findings
- Overview
- Therapy area focus (2002-06)
- Generic and biosimilar products
- Fentanyl
- Amoxicillin/clavulanate
- Omeprazole
- Azithromycin
- Estradot
- Generic outlook
- Biosimilar outlook
- Omnitrope
- Epoetin alpha
- Biosimilars in development
Chapter 6 Appendix
- IMS versus company-reported data reconciliation
- References
- Abbreviations
- Exchange rates
List of Tables
- Table 1: Sandoz Corporate Executive Committee, 2007
- Table 2: Generic peer-set overview , 2006
- Table 3: Novartis - operating revenue/cost analysis ($ m), 2002-06
- Table 4: Novartis - operating cost ratio analysis (% of total revenues), 2002-06
- Table 5: Key generic product overview, Sandoz top five product sales across the seven major markets, 2006
- Table 6: Generic drugs launched in 2006 by Sandoz
- Table 7: Sandoz's biosimilar product portfolio and pipeline, 2007
- Table 8: Exchange rates, 2006
List of Figures
- Figure 1: Historical ethical generic global sales performance for Sandoz and the generic peer set (% CAGR), 2002-06
- Figure 2: Sandoz's generic therapeutic focus versus generic Pharma peer set (%), 2006
- Figure 3: Sandoz's generic drug forecast ($ billion), 2006-12
- Figure 4: Percentage revenues attributed to generics launched in the US by Sandoz, 2002-06
- Figure 5: SWOT analysis, Sandoz
- Figure 6: Sandoz's M&A/divestment history, 2000-06
- Figure 7: Sandoz's corporate structure
- Figure 8: Revenue and annual growth rate in global ethical sales ($m), Sandoz, 2002-06
- Figure 9: Sandoz's total global ethical revenue and growth rate compared to generic peer set, 2001-06
- Figure 10: Sandoz's growth drivers of historical revenue performance ($m), 2002-06
- Figure 11: Novartis - operating revenue/cost analysis ($ billion), 2002-06
- Figure 12: Novartis - operating cost ratio analysis (% of total revenues), 2002-06
- Figure 13: Novartis - operating cost ratio versus peer-set, 2002-06
- Figure 14: Sandoz's top five products across the seven major markets ($m), 2006
- Figure 15: Sandoz's global generic sales by therapeutic class, 2006
- Figure 16: Sandoz's 2006 drug launches
- Figure 17: IMS versus company-reported ethical sales discrepancy for Sandoz ($m), 2006